Sana Biotechnology's allogeneic HIP technology achieved a first in T1D, showing insulin production and without ...

Vertex Pharmaceuticals ( VRTX) plunged after Q2 earnings and is now down 21% over the past year. The company has historically ...

What Happened: SACHS's recent move, as outlined in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday, involves purchasing 5,000 shares of Vertex Pharmaceuticals. The total ...

Even with the S&P 500 near an all-time high, there are plenty of compelling growth, dividend, and value stocks to buy now.

The RMR Group (Nasdaq: RMR) today announced on behalf of its managed joint venture that it has facilitated a $1.0 billion five-year, interest-only fixed rate mortgage financing with a weighted-average ...

Vertex reported quarterly earnings of 15 cents per share which beat the analyst consensus estimate of 14 cents per share. The ...

Vertex's late-stage pipeline also gives investors several lottery tickets with great odds. The drugmaker is evaluating ...

Vertex Pharmaceuticals recently reported a significant revenue jump to $2,965 million in Q2 2025. Despite this success, the ...

Fintel reports that on August 6, 2025, Wells Fargo upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from ...

Vertex Pharmaceuticals nosedived on Tuesday to hit a new all-time low following the termination of a clinical trial for an ...

Profits made by giants like Mc.Donalds and Walt Disney along with a a parade of stronger-than-expected profit reports from US ...

I think that's the case with Vertex. Here are seven reasons why Vertex is a no-brainer stock to buy on the dip.